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| INTRODUCTION
Hypochlorous acid (HOCl) is a potent microbicidal agent generated by the myeloperoxidase (MPO)-hydrogen peroxide (H 2 O 2 )-Chloride (Cl − ) system in phagocytic cells including neutrophils and plays a key role in innate immunity. have highlighted the mechanism through which HOCl mediates the destruction of the metal-ion derivatives of tetrapyrrole macrocyclic rings such as hemoproteins and vitamin B 12 (VB 12 ) derivatives. [12] [13] [14] [15] [16] [17] We have shown destruction of cyanocobalamin ( Figure 1A ), a common pharmacological form of VB 12 , mediated by HOCl, resulted in the generation of toxic molecular products such as chlorinated derivatives, different degradation products of corrin, the organic ring system of cobalamin, release of the toxic blood agents (CN − /cyanogen chloride [CNCl] ), and redox-active free cobalt (Co) through the formation of chloro-cyanocobalamin ( Figure 1B) . 15, 18 Interestingly, many of the disorders known to be associated with VB 12 deficiency are also associated with increased MPO/HOCl levels. [19] [20] [21] [22] [23] [24] For instance, deficiency of VB 12 is associated with neurodegenerative disorders including but not limited to Parkinson and Alzheimer disease and megaloblastic anemia, elevated blood homocysteine level (a risk factor for cardiovascular disease and adverse pregnancy outcomes). 19, 20, [22] [23] [24] [25] These negative effects are primarily because the most prominent function of cyanocobalamin is to act as cofactor in 2 major biochemical pathways; (i) in the conversion of homocysteine to methionine by methionine synthase and (ii) in the conversion of methylmalonyl CoA to succinyl CoA by methylmalonyl CoA mutase 26 ( Figure 1C ).
Many experiments have demonstrated that melatonin (N-acetyl-5-hydroxytryptamine) can protect against HOClmediated damage. 16, [27] [28] [29] [30] This ubiquitous molecule is found in a large cross-section of organisms, ranging from unicellular organism, fungi, and plants to higher invertebrate and vertebrate animals. 31 In humans, it is most commonly known to be a modulator of circadian rhythm and is produced in the pineal gland, from the amino acid tryptophan. [32] [33] [34] In addition, melatonin can be found in the gastrointestinal tract, cerebellum, retina, skin, ovary, liver, pancreas, kidneys, and the immune competent cells. 33, [35] [36] [37] [38] [39] [40] [41] Additionally, melatonin is also involved in immune enhancing, 35 anti-inflammatory pathway, 42, 43 and can inhibit cancer progression. 41, 44, 45 Several of melatonin's functions are mediated by the membranebound G protein-coupled receptors, MT1 and MT2. 46, 47 In addition to the receptor-mediated functions, melatonin performs various biochemical functions, for example acts as an antioxidant. Previously, melatonin has also been shown to be a major scavenger of HOCl. 48 In addition, melatonin has the ability to scavenge a variety of reactive oxygen species (ROS)/free radicals, such as H 2 O 2 , hydroxyl radical (
), alkoxyl radical, peroxyl radical, singlet oxygen, and nitric oxide. 40, [49] [50] [51] Importantly, melatonin also serves as an inhibitor for enzymes that generate ROS, such as MPO and eosinophil peroxidase, the major sources for hypohalous acids. 29, 30 In this work, we examined the ability of melatonin to prevent HOCl-mediated cyanocobalamin corrin destruction and subsequent release of the blood agents CN − /CNCl, and redox-active free Co release. Our results showed that melatonin prevents HOCl-mediated cyanocobalamin destruction and subsequent release of toxic agents. The conversion of several melatonin oxidation products suggests that the protective role of melatonin against HOCl-mediated cyanocobalamin destruction is at the expense of melatonin oxidation. Collectively, melatonin displays the ability to prevent VB 12 destruction in inflammatory conditions and could benefit patients with disorders associated with deficiency of this vitamin. ) prior to addition of 4000 μmol L −1 of HOCl, and the decreases in absorbance at 590 nm were monitored as a function of time. The rate of the reaction was calculated by the slope of the tangent drawn at the initial linear part of the curve. All experiments were performed in triplicates.
| Kinetic analysis

| High-performance liquid chromatography analysis
High-performance liquid chromatography analyses were carried out using a Shimadzu HPLC system equipped with an SCL-10A system controller, with a binary pump solvent delivery (LC-10 AD) module and an SIL-10 AD autoinjector connected to an SPD-M10A diode array detector and an RF-10A XL fluorescence detector. An Alltech 5-μm particle size, 4.6 × 150-mm reverse-phase octadecylsilica (C18) HPLC column was used.
| Detection of Cl-cyanocobalamin
Fifty microlitres of cyanocobalamin-HOCl reaction mixture was injected to analyze HOCl-mediated formation of Cl-cyanocobalamin and its modulation by melatonin. The photodiode array detector was set at 360 nm to monitor the chromatogram. The column was eluted isocratically at a flow rate of 2.0 mL min −1 with 20% acetonitrile and 80% water.
Each sample was analyzed in triplicate.
| Cyanocobalamin destruction and analysis of melatonin oxidation products
Fifty microlitres of cyanocobalamin-HOCl reaction mixture was injected to analyze HOCl-mediated destruction of cyanocobalamin and its prevention by melatonin. The column was eluted isocratically at a flow rate of 1.0 mL min −1 with 40% acetonitrile and 60% water. Each sample was analyzed in triplicate. To monitor cyanocobalamin, the photodiode array detector was set at 360 nm to obtain the chromatogram. For analyzing melatonin consumption and formation of melatonin oxidation products, the photodiode array detector was set at 260 nm. AFMK was detected by its intrinsic fluorescence by setting the fluorescence detector at excitation 321 nm and emission 465 nm to monitor the chromatogram. Each sample was analyzed in triplicate.
| Colorimetric detection of CNCl
Cyanogen chloride was detected colorimetrically using the pyridine-1,3-dimethyl barbituric acid reagent as described previously. 15, 52 In this assay, CNCl reacts with pyridine to form a dialdehyde, glutacon dialdehyde, which then reacts with 1,3-dimethyl barbituric acid and condenses to form a violet-colored polymethine dye. The composition of the pyridine-1,3-dimethyl barbituric acid (coloring reagent) was as follows: 1.2 g of 1,3-dimethyl barbituric acid was dissolved in a mixture of 12.8 mL of water and 6 mL of pyridine, and then 1.2 mL of HCl was added to the solution to bring the total volume to 20 mL. Cyanocobalamin (100 μmol L −1 ) was treated with 3000 μmol L −1 of HOCl in the presence or absence of 3000 μmol L −1 melatonin at 10°C for 2 hours. Following which, the reaction was stopped by adding high molar excess of methionine. Then, coloring reagent (500 μL) was added to 500 μL of cyanocobalaminHOCl reaction mixture and was incubated for 15 minutes at 10°C. The absorbance of the resulting violet-colored solution was measured at 587.5 nm against the cyanocobalaminHOCl reaction mixture (without addition of coloring reagent, but diluted with an equal volume of water) to subtract the absorbance due to residual cyanocobalamin. The amount of CNCl was determined from the extinction coefficient of 1.03 × 10 5 mol L −1 cm − 1 for the violet-colored complex. As HOCl is unstable, the stock solution was freshly prepared on a daily basis, stored on ice, and used within 1 hour of preparation. For further experimentations, dilutions were made from the stock solution using 200 mmol L −1 phosphate buffer, pH 7.4, to give working solutions of lower HOCl concentration.
| Cyanocobalamin preparation
Cyanocobalamin stock solution was prepared by dissolving cyanocobalamin in distilled water. The concentration of the stock solution was determined spectrophotometrically at 361 nm (ε = 27.5 mmol L −1 cm −1 ).
| Melatonin preparation
Melatonin was prepared by dissolving 92 mg of mol L −1 melatonin elt in 1 mL of DMF, to give a solution of concentration 396 mmol L −1 . Melatonin solution prepared in this manner was shielded from light and kept on ice and used within 1 hr of preparation.
| RESULTS
We first utilized HPLC techniques to investigate the effect of melatonin in preventing the HOCl-mediated cyanocobalamin destruction by preincubating cyanocobalamin with increasing molar ratios of melatonin:HOCl (0:1 up to 2:1) prior to HOCl addition and HPLC. Under our experimental conditions, cyanocobalamin eluted around 3 min and was identified based on its characteristic UV-Vis spectra (360, 540 and 550 nm) obtained from the diode array detector (Figure 2A Chromatograms were monitored at 360 nm. The position of the cyanocobalamin and Cl-cyanocobalamin peaks are marked by blue and black arrows, respectively. The data shown are a representative of 3 independent experiments; B, UV-Vis spectra of the cyanocobalamin (dotted line) and Cl-cyanocobalamin (solid lines) peaks, as obtained from the diode array detector. The Cl-cyanocobalamin spectra were plotted as a function of melatonin:HOCl molar ratios (ratios shown in inset); C, Relative amount of cyanocobalamin and Cl-cyanocobalamin as calculated from the area under the curve for each peak were plotted as a function of melatonin:HOCl molar ratios. For cyanocobalamin, the area under the curve for cyanocobalamin alone was defined as 100%, while for Cl-cyanocobalamin, the area under the curve at 0 melatonin was defined as 100% and subsequent areas were normalized to those values. The data points are the average of 3 independent experiments, and the error bars represent the standard error of measurements; D, Kinetic traces for the cyanocobalamin-HOCl reaction monitored at 590 nm, showing the formation of Clcyanocobalamin, as a function of different molar ratios of melatonin:HOCl. These data are average of 3 independent experiments; E, Pseudo-firstorder rate constants of formation of Cl-cyanocobalamin, plotted as a function of melatonin:HOCl molar ratios. The data points are the average of 3 independent experiments, and the error bars represent the standard error of measurements region (from 550 to 590 nm), and was identified to be as Clcyanocobalamin, in accordance with our earlier observation 15 ( Figure 2B ). Adding 20 μmol L −1 of melatonin to the reaction mixture (melatonin−HOCl) decreased in Cl-cyanocobalamin peak and the restoration of the cyanocobalamin peak. Further increasing the melatonin concentration leads to complete restoration of the cyanocobalamin peak in a concentrationdependent manner. The area under the curve for the cyanocobalamin peak and Cl-cyanocobalamin peak was plotted as a function of melatonin:HOCl ratio ( Figure 2C ). The relative amount of Cl-cyanocobalamin decreased linearly until melatonin:HOCl ratio 0.4:1, after which the Cl-cyanocobalamin level gradually plateaued, and saturating at melatonin:HOCl ratio 1:1 ( Figure 2C, red curve) . A parallel trend was observed for the amount of cyanocobalamin ( Figure 2C , black curve). Next, to study the effect of melatonin on the kinetics of the process of HOCl-mediated Clcyanocobalamin formation, UV-Vis spectrophotometry was used. To phase out the effect of melatonin on the spectra of cyanocobalamin, the increase in absorbance was monitored at 590 nm, where melatonin (at the concentrations used) had no interference. Cyanocobalamin (20 μmol L −1 ) was preincubated with different melatonin:HOCl molar ratios (0-2:1), and then, 450 μmol L −1 HOCl was added to the reaction mixture and an increase in absorbance at 590 nm was recorded. Figure 2D shows the profile of the absorbance increase at 590 nm, as a function of time for different melatonin:HOCl ratios. In the absence of melatonin, HOCl caused the absorbance to increase exponentially, and signal saturated at approximately 500 s. When cyanocobalamin was pretreated with melatonin, we observed a decrease in the amplitude of the absorbance change, as well as a decrease in the slope of the curve, signifying the rate. Indeed, when the pseudo-firstorder rate of Cl-cyanocobalamin formation was plotted as a function of melatonin:HOCl ratio, we observed that the rate of Cl-cyanocobalamin formation decreased linearly until 0.6:1, after which the rate plateaued and saturated around 2:1 melatonin:HOCl ratio. Thus, we conclude that melatonin can effectively prevent HOCl-mediated Cl-cyanocobalamin formation.
As reported earlier, the process of HOCl-mediated cyanocobalamin destruction involves 2 distinct steps, first conversion of cyanocobalamin to Cl-cyanocobalamin and next oxidative destruction of Cl-cyanocobalamin. 15 As our current results indicated that melatonin prevents HOCl-mediated generation of Cl-cyanocobalamin, we hypothesized that melatonin will prevent HOCl-mediated cyanocobalamin destruction and subsequent generation of CNCl. To test our hypothesis, cyanocobalamin (20 μmol L ). HPLC analyses revealed that in the absence of melatonin, HOCl treatment led to complete destruction of cyanocobalamin, while pretreatment with 1:1 melatonin:HOCl prevented cyanocobalamin destruction by 96% (see Figure 3A and Figure 3A was preincubated with different melatonin:HOCl molar ratios (0-1:1), and then, 4000 μmol L −1 HOCl was added to the reaction mixture and decrease in absorbance at 590 nm was recorded. Figure 3B shows the pseudo-first-order rate of HOCl-mediated cyanocobalamin corrin ring destruction plotted as a function of melatonin:HOCl ratio. As the melatonin:HOCl ratio increased, we observed a linear decrease in the rate of cyanocobalamin destruction, which ultimately approached ~0 at around 0.22:1 melatonin:HOCl ratio. As our results showed that melatonin effectively prevents HOClmediated cyanocobalamin corrin destruction, we wanted to test the role of melatonin in inhibiting HOCl-mediated CNCl generation from cyanocobalamin. As shown in Figure 3C . To understand the mechanism of how melatonin prevents HOCl-mediated cyanocobalamin destruction, we compared the melatonin oxidation products that were formed when HOCl oxidized melatonin in the presence and absence of cyanocobalamin. The chromatograms (see Figure 4A ) were monitored at 260 nm to phase out the interference from any unreacted cyanocobalamin/Cl-cyanocobalamin derivatives. Under our chromatographic conditions, control unreacted melatonin eluted around ~11 minutes and was identified from its characteristic spectra (purple trace in Figure 4A ). As expected, cyanocobalamin alone and cyanocobalamin treated with HOCl in the absence of melatonin did not show any major peaks ( Figure 4A , traces labeled as "cyanocobalamin" and "cyanocobalamin +HOCl"). In contrast, the melatonin +HOCl and cyanocobalamin + melatonin +HOCl reaction mixtures displayed 3 major UV-absorbing peaks labeled as "Peak I," "Peak II," and "Peak III". The retention time and spectral characteristics of the Peak I-III are listed in Table 1 . The spectral features of the compounds eluting as "Peak II" and "Peak III" are very similar, while "Peak I" shows a distinct redshift ( Figure 4B ). We also detected the formation of the fluorescent melatonin oxidation product N-[3-[2-(formylamino)-5-methoxyphenyl]-3-oxypropyl]-acetamide (AFMK) (chromatogram not shown) as reported earlier by Dellegar et al. 51 and Ximenes et al. who also described the formation of a melatonin dimer. 55 Although previous reports suggested formation of 2-hydroxymelatonin as a product of HOCl-induced melatonin oxidation, 51 we failed to identify 2-hydroxymelatonin, from the spectral features of the 3 peaks. 2-hydroxymelatonin is relatively unstable and could easily convert to its keto tautomer, an indolinone, a rather lipophilic molecule. 56 Detailed mass spectrometric and NMR studies are currently underway in our laboratory to characterize these novel melatonin oxidation products. The relative amount of the melatonin oxidation product (as judged by the area under the curve for each peak), formed when melatonin reacted with HOCl in the presence or absence of cyanocobalamin, is shown in Figure 4C . We observed similar trend for the melatonin +HOCl and cyanocobalamin + melatonin +HOCl reaction mixtures, respectively, indicating that melatonin protects HOCl-mediated cyanocobalamin corrin ring destruction by virtue of its ability to compete and scavenge HOCl. Chromatograms were monitored at 260 nm. The peak corresponding to unreacted melatonin is labeled as "Melatonin". Three other, major UVabsorbing peaks are labeled as I, II, and III, respectively. The data shown are a representative of 3 independent experiments; B, UV-Vis spectrum of peak I, II, and III as obtained from the diode array detector; C, Relative amount of each product generated as calculated from the area under the curve for each peak. AFMK was detected via fluorescence detector (chromatogram not shown) as mentioned in the Materials and Methods section.
The data shown are a representative of 3 independent experiments, and the error bars represent the standard error of measurements
| DISCUSSION
Here, we showed that melatonin is capable in preventing HOCl-mediated VB 12 destruction and the generation of toxic molecular products such as chlorinated derivatives, corrin ring cleavage products, the toxic blood agents CN − and
CNCl, and redox-active free cobalt. The identification of several melatonin oxidation products clearly suggests that corrin ring protection was at the expense of melatonin. Our work may establish a direct mechanistic link by which melatonin exerts its antioxidant protective effect of VB 12 under chronic inflammatory conditions where MPO-chlorinating activity is elevated.
In human, melatonin and VB 12 complement each other as antioxidants and in the regulation of circadian rhythm. Vitamin B 12 exerts a direct influence on melatonin causing an earlier release of melatonin at night, which resets the sleep-wake cycle, by acting directly on the pineal gland to provoke a faster release of melatonin. 57 Vitamin B 12 also causes melatonin to drop off faster by sensitizing the body to morning light. [58] [59] [60] Very serious sleep-wake disorders have been successfully treated with VB 12 in the methylcobalamin form. [58] [59] [60] [61] Here, we show a novel mechanistic role of melatonin, in which it can act to prevent the corrin ring destruction under inflammatory diseases where HOCl is elevated therefore preventing VB 12 deficiency under such conditions. Vitamin B 12 is not only used for treating and preventing VB 12 deficiency, but also used for treating several conditions related to memory loss, immune system, aging, heart disease, male infertility, diabetes, sleep disorders, depression, mental disorders, and inflammation. 62, 63 The safety in the 64 71 It has been generally perceived that the development of atrophic gastritis is due to chronic Helicobacter pylori (H. pylori) infection, which leads to extensive infiltration of the gastric mucosa by neutrophils. 72 MPO in neutrophils/macrophages amplifies the oxidative potential of H 2 O 2 that induces gastric mucosal damage, and thus, MPO is suspected to play a role in H. pylori -induced gastric injury. 73 The development of atrophic gastritis subsequent to H. pylori infection is determined by host-bacterial interaction with studies favoring host-related factors. 74 It has been shown that host MPO genetic polymorphism may play an important role in the pathogenesis of atrophic gastritis upon H. pylori infection. 75 In addition to lack of intrinsic factor, VB 12 deficiency in pernicious anemia and atrophic gastritis could be explained in part by enhancement of MPO activity that leads to distortion of the corrin ring of cyanocobalamin by HOCl. 15 Destruction of cyanocobalamin tetrapyrrole macrocycle by HOCl is also believed to be a leading event in cell injury, because it is tightly coupled with the generation of several undesired toxic molecules such as redox-active transition metals (e.g, cobalt and iron), which, through Fenton reaction forms highly reactive free radicals such as • OH. [76] [77] [78] [79] [80] [81] VB 12 destruction will also lead to the elevation of plasma homocysteine and methylmalonyl CoA levels by inhibiting methionine synthase and l-methyl malonyl CoA mutase. 82 A scheme of MPO catalysis that incorporates our current findings is presented in Figure 5 . In this working model, stimulation of neutrophils activates the membrane-bound NADPH oxidase, which converts molecular oxygen to O 2
•− . 15 Melatonin modulates HOCl-mediated cyanocobalamin destruction in a concentration-dependent fashion by at least through 2 distinct pathways ( Figure 5) . Firstly, by serving as an inhibitor of MPO by its ability to act as a 1e − substrate for MPO Compounds I and II (MPOFe(IV) = O complex), or binding directly to MPO above the heme iron forming melatonin-MPO-Fe(III) complex and secondly, by direct scavenging of HOCl. 30, 48, 84 In the presence of melatonin, rapid kinetic studies suggested that the Compound I oxidizes melatonin through 2 sequential 1-electron steps, forming Compound II and MPO-Fe(III), respectively. 85 Through this mechanism, melatonin inhibits MPO-chlorinating activity but not the peroxidase activity. 85 Alternatively, melatonin binds directly to MPOFe(III) presumably above the heme moiety, to readily promote reversible inhibition of peroxidase activity, to form a dead-end melatonin-MPO-Fe(III) complex, 85 and secondly, by its ability to directly scavenge HOCl may protect cyanocobalamin from HOCl-mediated degradation. 40, 51 Thus, one mechanism through which melatonin might prevent VB 12 -mediated HOCl damage in vivo is by minimizing the accumulation of HOCl during steady-state catalysis. As depicted in Figure 4 and 5, the effect of melatonin on MPO-Fe(III) peroxidase activity will depend on multiple factors, including the bioavailability of melatonin vs H 2 O 2 , the affinity of MPO-Fe(III) for melatonin vs H 2 O 2 , and the rate of melatonin-MPO-Fe(III) breakdown. Melatonin functions as an antioxidant has been proven not only through its capacity to scavenge a variety of free radical and ROS, but also through its ability to chelate transition metals (e.g, iron (III), copper, and zinc), a major source of ROS, [86] [87] [88] thereby resulting in the lowering of ROS harmful effects such as lipid peroxidation, protein oxidation, and DNA damage. 27, 35, 49, [87] [88] [89] Importantly, melatonin oxidation products have no biologically harmful consequences when it reacts with HOCl; therefore, its use as antioxidant is exceptional among other HOCl scavengers (such as taurine, cystine, cysteine, and uric acid). 29, 90 For example, 2-hydroxymelatonin is produced 54 at a sufficient rate by the reaction of melatonin with HOCl to protect catalase against HOCl-mediated inactivation. 48 Collectively, inhibiting the MPO-chlorinating activity or scavenging HOCl by melatonin might be a useful therapeutic approach in reducing VB 12 deficiency and eliminating the subsequent sequelae of the toxic cyanocobalamin degradation products generated by HOCl in a wide variety of inflammatory conditions.
